A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults

Clinical Immunology

Volumn 168, Issue , 2016, Pages 72-87

  Pillet, Stéphane ^a,b   Aubin, Éric ^a   Trépanier, Sonia ^a   Bussière, Diane ^a   Dargis, Michèle ^a   Poulin, Jean François ^c   Yassine Diab, Bader ^c   Ward, Brian J ^b   Landry, Nathalie ^a  

^a Medicago Inc   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c Immune Carta Services   (Canada)

Author keywords

Cell mediated immunity; Cross reactive response; Nicotiana benthamiana; Plant derived quadrivalent influenza vaccine; Safety and immunogenicity; Virus like particles

Indexed keywords

CROSS REACTING ANTIBODY; GAMMA INTERFERON; HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; PLANT BASED QUADRIVALENT VIRUS LIKE PARTICLE VACCINE; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS ANTIBODY;

2009 H1N1 INFLUENZA; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HEMAGGLUTINATION INHIBITION; HONG KONG INFLUENZA; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA A (H3N2); INFLUENZA VACCINATION; INJECTION SITE PAIN; MALE; MEMORY T LYMPHOCYTE; MYALGIA; NICOTIANA BENTHAMIANA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SWELLING; T LYMPHOCYTE; VIRUS LIKE AGENT; VIRUS STRAIN; ADOLESCENT; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; CROSS REACTION; DOSE RESPONSE; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS; METABOLISM; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TOBACCO; TREATMENT OUTCOME; VACCINATION; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CROSS REACTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; FLOW CYTOMETRY; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON-GAMMA; MALE; MIDDLE AGED; T-LYMPHOCYTES; TOBACCO; TREATMENT OUTCOME; VACCINATION; VACCINES, VIRUS-LIKE PARTICLE; YOUNG ADULT;

EID: 84973565832     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2016.03.008     Document Type: Article

References (73)

1. [1] Thompson, W.W., Shay, D.K., Weintraub, E., Brammer, L., Bridges, C.B., Cox, N.J., Fukuda, K., Influenza-associated hospitalizations in the United States. JAMA 292 (2004), 1333–1340.
2. [2] Irving, S.A., Patel, D.C., Kieke, B.A., Donahue, J.G., Vandermause, M.F., Shay, D.K., Belongia, E.A., Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a defined population over four seasons: 2004-2005 through 2007-2008. Influenza Other Respir. Viruses 6 (2012), 37–43.
3. [3] Bridges, C.B., Thompson, W.W., Meltzer, M.I., Reeve, G.R., Talamonti, W.J., Cox, N.J., Lilac, H.A., Hall, H., Klimov, A., Fukuda, K., Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 284 (2000), 1655–1663.
4. [4] Belongia, E.A., Kieke, B.A., Donahue, J.G., Greenlee, R.T., Balish, A., Foust, A., Lindstrom, S., Shay, D.K., G. Marshfield Influenza Study, Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004–2005 season to the 2006–2007 season. J. Infect. Dis. 199 (2009), 159–167.
5. [5] Belshe, R.B., Coelingh, K., Ambrose, C.S., Woo, J.C., Wu, X., Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 28 (2010), 2149–2156.
6. [6] Rota, P.A., Wallis, T.R., Harmon, M.W., Rota, J.S., Kendal, A.P., Nerome, K., Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 175 (1990), 59–68.
7. [7] Reed, C., Meltzer, M.I., Finelli, L., Fiore, A., Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 30 (2012), 1993–1998.
8. [8] Kieninger, D., Sheldon, E., Lin, W.Y., Yu, C.J., Bayas, J.M., Gabor, J.J., Esen, M., Fernandez Roure, J.L., Narejos Perez, S., Alvarez Sanchez, C., Feng, Y., Claeys, C., Peeters, M., Innis, B.L., Jain, V., Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged >/=18 years. BMC Infect. Dis., 13, 2013, 343.
9. [9] Cadorna-Carlos, J.B., Nolan, T., Borja-Tabora, C.F., Santos, J., Montalban, M.C., DE Looze, F.J., Eizenberg, P., Hall, S., Dupuy, M., Hutagalung, Y., Pepin, S., Saville, M., Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: a randomized, controlled, phase III trial. Vaccine 33 (2015), 2485–2492.
10. [10] Langley, J.M., Wang, L., Aggarwal, N., Bueso, A., Chandrasekaran, V., Cousin, L., Halperin, S.A., Li, P., Liu, A., McNeil, S., Mendez, L.P., Rivera, L., Innis, B.L., Jain, V.K., Immunogenicity and reactogenicity of an inactivated quadrivalent influenza vaccine administered intramuscularly to children 6 to 35 months of age in 2012-2013: a randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial. J. Pediatr. Infect. Dis. Soc. 4 (2015), 242–251.
11. [11] Tsurudome, Y., Kimachi, K., Okada, Y., Matsuura, K., Ooyama, Y., Ibaragi, K., Kino, Y., Ueda, K., Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan. Microbiol. Immunol., 2015.
12. [12] Furuya, Y., Chan, J., Regner, M., Lobigs, M., Koskinen, A., Kok, T., Manavis, J., Li, P., Mullbacher, A., Alsharifi, M., Cytotoxic T cells are the predominant players providing cross-protective immunity induced by {gamma}-irradiated influenza A viruses. J. Virol. 84 (2010), 4212–4221.
13. [13] Hillaire, M.L., VAN Trierum, S.E., Kreijtz, J.H., Bodewes, R., Geelhoed-Mieras, M.M., Nieuwkoop, N.J., Fouchier, R.A., Kuiken, T., Osterhaus, A.D., Rimmelzwaan, G.F., Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells. J. Gen. Virol. 92 (2011), 2339–2349.
14. [14] Kreijtz, J.H., Bodewes, R., VAN DEN Brand, J.M., DE Mutsert, G., Baas, C., VAN Amerongen, G., Fouchier, R.A., Osterhaus, A.D., Rimmelzwaan, G.F., Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. Vaccine 27 (2009), 4983–4989.
15. [15] Kreijtz, J.H., DE Mutsert, G., VAN Baalen, C.A., Fouchier, R.A., Osterhaus, A.D., Rimmelzwaan, G.F., Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J. Virol. 82 (2008), 5161–5166.
16. [16] Duvvuri, V.R., Marchand-Austin, A., Eshaghi, A., Patel, S.N., Low, D.E., Gubbay, J.B., Potential T cell epitopes within swine-origin triple reassortant influenza A (H3N2) variant virus which emerged in 2011: an immunoinformatics study. Vaccine 30 (2012), 6054–6063.
17. [17] Duvvuri, V.R., Moghadas, S.M., Guo, H., Duvvuri, B., Heffernan, J.M., Fisman, D.N., Wu, G.E., Wu, J., Highly conserved cross-reactive CD4 + T-cell HA-epitopes of seasonal and the 2009 pandemic influenza viruses. Influenza Other Respir. Viruses 4 (2010), 249–258.
18. [18] Lee, L.Y., Ha do, L.A., Simmons, C., DE Jong, M.D., Chau, N.V., Schumacher, R., Peng, Y.C., McMichael, A.J., Farrar, J.J., Smith, G.L., Townsend, A.R., Askonas, B.A., Rowland-Jones, S., Dong, T., Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J. Clin. Investig. 118 (2008), 3478–3490.
19. [19] Terajima, M., Babon, J.A., Co, M.D., Ennis, F.A., Cross-reactive human B cell and T cell epitopes between influenza A and B viruses. Virol. J., 10, 2013, 244.
20. [20] Leddon, S.A., Richards, K.A., Treanor, J.J., Sant, A.J., Abundance and specificity of influenza reactive circulating memory Tfh and non-Tfh CD4 T cells in healthy adults. Immunology, 2015.
21. [21] D'Aoust, M.A., Couture, M.M., Charland, N., Trepanier, S., Landry, N., Ors, F., Vezina, L.P., The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol. J. 8 (2010), 607–619.
22. [22] Landry, N., Pillet, S., Favre, D., Poulin, J.F., Trepanier, S., Yassine-Diab, B., Ward, B.J., Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens. Clin. Immunol. 154 (2014), 164–177.
23. [23] Landry, N., Ward, B.J., Trepanier, S., Montomoli, E., Dargis, M., Lapini, G., Vezina, L.P., Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One, 5, 2010, e15559.
24. [24] Scotti, N., Rybicki, E.P., Virus-like particles produced in plants as potential vaccines. Expert Rev. Vaccines 12 (2013), 211–224.
25. [25] Skowronski, D.M., Janjua, N.Z., DE Serres, G., Sabaiduc, S., Eshaghi, A., Dickinson, J.A., Fonseca, K., Winter, A.L., Gubbay, J.B., Krajden, M., Petric, M., Charest, H., Bastien, N., Kwindt, T.L., Mahmud, S.M., VAN Caeseele, P., Li, Y., Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One, 9, 2014, e92153.
26. [26] Pillet, S., Racine, T., Nfon, C., Di Lenardo, T.Z., Babiuk, S., Ward, B.J. et al., Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets. Vaccine 33 (2015), 6282–6289.
27. [27] WHO, Manual on animal influenza diagnosis and surveillance. Department of Communicable Disease Surveillance and Response. World Health Organisation Global Influenza Program, 2002.
28. [28] Potter, C.W., Oxford, J.S., Determinants of immunity to influenza infection in man. Br. Med. Bull. 35 (1979), 69–75.
29. [29] Baz, M., Luke, C.J., Cheng, X., Jin, H., Subbarao, K., H5N1 vaccines in humans. Virus Res. 178 (2013), 78–98.
30. [30] Schotsaert, M., Saelens, X., Leroux-Roels, G., Influenza vaccines: T-cell responses deserve more attention. Expert Rev. Vaccines 11 (2012), 949–962.
31. [31] C.f.P.M.P. CPMP, Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96. 1997, The European Agency for the Evaluation of Medicinal Products (EMEA).
32. [32] Betts, M.R., Koup, R.A., Detection of T-cell degranulation: CD107a and b. Methods Cell Biol. 75 (2004), 497–512.
33. [33] Ward, B.J., Landry, N., Trepanier, S., Mercier, G., Dargis, M., Couture, M., D'Aoust, M.A., Vezina, L.P., Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines. Vaccine 32 (2014), 6098–6106.
34. [34] Fotisch, K., Altmann, F., Haustein, D., Vieths, S., Involvement of carbohydrate epitopes in the IgE response of celery-allergic patients. Int. Arch. Allergy Immunol. 120 (1999), 30–42.
35. [35] Foetisch, K., Westphal, S., Lauer, I., Retzek, M., Altmann, F., Kolarich, D., Scheurer, S., Vieths, S., Biological activity of IgE specific for cross-reactive carbohydrate determinants. J. Allergy Clin. Immunol. 111 (2003), 889–896.
36. [36] Westphal, S., Kolarich, D., Foetisch, K., Lauer, I., Altmann, F., Conti, A., Crespo, J.F., Rodriguez, J., Enrique, E., Vieths, S., Scheurer, S., Molecular characterization and allergenic activity of Lyc e 2 (beta-fructofuranosidase), a glycosylated allergen of tomato. Eur. J. Biochem. 270 (2003), 1327–1337.
37. [37] Moro-Garcia, M.A., Alonso-Arias, R., Lopez-Larrea, C., When aging reaches CD4 + T-cells: phenotypic and functional changes. Front. Immunol., 4, 2013, 107.
38. [38] Sallusto, F., Geginat, J., Lanzavecchia, A., Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22 (2004), 745–763.
39. [39] Gorse, G.J., Falsey, A.R., Ozol-Godfrey, A., Landolfi, V., Tsang, P.H., Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults. Vaccine 33 (2015), 1151–1159.
40. [40] Tinoco, J.C., Pavia-Ruz, N., Cruz-Valdez, A., Aranza Doniz, C., Chandrasekaran, V., Dewe, W., Liu, A., Innis, B.L., Jain, V.K., Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged >/=18 years: a phase III, randomized trial. Vaccine 32 (2014), 1480–1487.
41. [41] Verschoor, C.P., Singh, P., Russell, M.L., Bowdish, D.M., Brewer, A., Cyr, L., Ward, B.J., Loeb, M., Microneutralization assay titres correlate with protection against seasonal influenza H1N1 and H3N2 in children. PLoS One, 10, 2015, e0131531.
42. [42] Sasaki, S., Jaimes, M.C., Holmes, T.H., Dekker, C.L., Mahmood, K., Kemble, G.W., Arvin, A.M., Greenberg, H.B., Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J. Virol. 81 (2007), 215–228.
43. [43] Vigano, A., Giacomet, V., Pariani, E., Giani, E., Manfredini, V., Bedogni, G., Erba, P., Amendola, A., Zanetti, A., Zuccotti, G., Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial. Clin. Vaccine Immunol. 18 (2011), 1503–1509.
44. [44] Poder, A., Simurka, P., Li, P., Roy-Ghanta, S., Vaughn, D., An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age. Vaccine 32 (2014), 1121–1129.
45. [45] Eidem, S., Tete, S.M., Jul-Larsen, A., Hoschler, K., Montomoli, E., Brokstad, K.A., Cox, R.J., Persistence and avidity maturation of antibodies to A(H1N1)pdm09 in healthcare workers following repeated annual vaccinations. Vaccine 33 (2015), 4146–4154.
46. [46] Loebermann, M., Voss, U., Meyer, S., Bosse, D., Fritzsche, C., Klammt, S., Frimmel, S., Riebold, D., Reisinger, E.C., Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination. PLoS One, 8, 2013, e70866.
47. [47] Nabeshima, S., Kashiwagi, K., Murata, M., Kanamoto, Y., Furusyo, N., Hayashi, J., Antibody response to influenza vaccine in adults vaccinated with identical vaccine strains in consecutive years. J. Med. Virol. 79 (2007), 320–325.
48. [48] Wei, C.J., Boyington, J.C., Dai, K., Houser, K.V., Pearce, M.B., Kong, W.P., Yang, Z.Y., Tumpey, T.M., Nabel, G.J., Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci. Transl. Med., 2, 2010, 24ra21.
49. [49] Roy-Ghanta, S., VAN DER Most, R., Li, P., Vaughn, D.W., Responses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: a randomized, observer-blind, controlled study. J. Infect. Dis. 210 (2014), 1419–1430.
50. [50] Sun, X., Jayaraman, A., Maniprasad, P., Raman, R., Houser, K.V., Pappas, C., Zeng, H., Sasisekharan, R., Katz, J.M., Tumpey, T.M., N-linked glycosylation of the hemagglutinin protein influences virulence and antigenicity of the 1918 pandemic and seasonal H1N1 influenza A viruses. J. Virol. 87 (2013), 8756–8766.
51. [51] Job, E.R., Deng, Y.M., Barfod, K.K., Tate, M.D., Caldwell, N., Reddiex, S., Maurer-Stroh, S., Brooks, A.G., Reading, P.C., Addition of glycosylation to influenza A virus hemagglutinin modulates antibody-mediated recognition of H1N1 2009 pandemic viruses. J. Immunol. 190 (2013), 2169–2177.
52. [52] Clark, E.A., Ledbetter, J.A., How B and T cells talk to each other. Nature 367 (1994), 425–428.
53. [53] Chiu, C., Ellebedy, A.H., Wrammert, J., Ahmed, R., B cell responses to influenza infection and vaccination. Curr. Top. Microbiol. Immunol. 386 (2015), 381–398.
54. [54] Zens, K.D., Farber, D.L., Memory CD4 T cells in influenza. Curr. Top. Microbiol. Immunol. 386 (2015), 399–421.
55. [55] McElhaney, J.E., Coler, R.N., Baldwin, S.L., Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults. Expert Rev. Vaccines 12 (2013), 759–766.
56. [56] Hoft, D.F., Babusis, E., Worku, S., Spencer, C.T., Lottenbach, K., Truscott, S.M., Abate, G., Sakala, I.G., Edwards, K.M., Creech, C.B., Gerber, M.A., Bernstein, D.I., Newman, F., Graham, I., Anderson, E.L., Belshe, R.B., Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J. Infect. Dis. 204 (2011), 845–853.
57. [57] Subbramanian, R.A., Basha, S., Shata, M.T., Brady, R.C., Bernstein, D.I., Pandemic and seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination. Vaccine 28 (2010), 8258–8267.
58. [58] Mohn, K.G., Bredholt, G., Brokstad, K.A., Pathirana, R.D., Aarstad, H.J., Tondel, C., Cox, R.J., Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children. J. Infect. Dis. 211 (2015), 1541–1549.
59. [59] Makedonas, G., Betts, M.R., Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection. Springer Semin. Immunopathol. 28 (2006), 209–219.
60. [60] Moris, P., VAN DER Most, R., Leroux-Roels, I., Clement, F., Drame, M., Hanon, E., Leroux-Roels, G.G., VAN Mechelen, M., H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J. Clin. Immunol. 31 (2011), 443–454.
61. [61] Seder, R.A., Darrah, P.A., Roederer, M., T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8 (2008), 247–258.
62. [62] McKinstry, K.K., Dutton, R.W., Swain, S.L., Strutt, T.M., Memory CD4 T cell-mediated immunity against influenza A virus: more than a little helpful. Arch. Immunol. Ther. Exp. 61 (2013), 341–353.
63. [63] Teijaro, J.R., Verhoeven, D., Page, C.A., Turner, D., Farber, D.L., Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms. J. Virol. 84 (2010), 9217–9226.
64. [64] Forrest, B.D., Pride, M.W., Dunning, A.J., Capeding, M.R., Chotpitayasunondh, T., Tam, J.S., Rappaport, R., Eldridge, J.H., Gruber, W.C., Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin. Vaccine Immunol. 15 (2008), 1042–1053.
65. [65] Mayer, K.D., Mohrs, K., Crowe, S.R., Johnson, L.L., Rhyne, P., Woodland, D.L., Mohrs, M., The functional heterogeneity of type 1 effector T cells in response to infection is related to the potential for IFN-gamma production. J. Immunol. 174 (2005), 7732–7739.
66. [66] Teijaro, J.R., Turner, D., Pham, Q., Wherry, E.J., Lefrancois, L., Farber, D.L., Cutting edge: tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J. Immunol. 187 (2011), 5510–5514.
67. [67] Farber, D.L., Yudanin, N.A., Restifo, N.P., Human memory T cells: generation, compartmentalization and homeostasis. Nat. Rev. Immunol. 14 (2014), 24–35.
68. [68] Laidlaw, B.J., Zhang, N., Marshall, H.D., Staron, M.M., Guan, T., Hu, Y., Cauley, L.S., Craft, J., Kaech, S.M., CD4(+) T cell help guides formation of CD103(+) lung-resident memory CD8(+) T cells during influenza viral infection. Immunity 41 (2014), 633–645.
69. [69] Wilkinson, T.M., Li, C.K., Chui, C.S., Huang, A.K., Perkins, M., Liebner, J.C., Lambkin-Williams, R., Gilbert, A., Oxford, J., Nicholas, B., Staples, K.J., Dong, T., Douek, D.C., McMichael, A.J., Xu, X.N., Preexisting influenza-specific CD4 + T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18 (2012), 274–280.
70. [70] Richards, K.A., Topham, D., Chaves, F.A., Sant, A.J., Cutting edge: CD4 T cells generated from encounter with seasonal influenza viruses and vaccines have broad protein specificity and can directly recognize naturally generated epitopes derived from the live pandemic H1N1 virus. J. Immunol. 185 (2010), 4998–5002.
71. [71] Appay, V., VAN Lier, R.A., Sallusto, F., Roederer, M., Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 73 (2008), 975–983.
72. [72] Hendriks, J., Gravestein, L.A., Tesselaar, K., VAN Lier, R.A., Schumacher, T.N., Borst, J., CD27 is required for generation and long-term maintenance of T cell immunity. Nat. Immunol. 1 (2000), 433–440.
73. [73] Lin, J., Somanathan, S., Roy, S., Calcedo, R., Wilson, J.M., Lung homing CTLs and their proliferation ability are important correlates of vaccine protection against influenza. Vaccine 28 (2010), 5669–5675.